In this workshop, you will learn to align regulatory writing and operations for faster, high-quality global submissions. Discover how early collaboration, shared standards, and smart planning reduce rework, risks, and delays.
In today's increasingly complex regulatory environment, the pressure to accelerate global submissions while maintaining the highest quality standards has never been greater. A successful submission is not merely a collection of documents: it is a meticulously constructed, interconnected dossier that must be clear, navigable, and compliant with diverse health authority (HA) technical requirements. All too often, a functional divide between regulatory writing and regulatory operations teams creates significant challenges, leading to last-minute fire drills, costly rework, and potential submission delays. Common pain points include misaligned content plans, incorrect document referencing, broken hyperlinks, and eleventh-hour scrambles to accommodate regional differences.
This presentation will detail a proactive, integrated model for "building a bridge" between regulatory writing and operations. Drawing from real-world case studies, we will explore the tangible benefits of early and continuous collaboration. We will discuss practical strategies for establishing shared submission standards, developing a robust hyperlink strategy, and planning for global submissions from the outset. By treating the submission process as an integrated partnership rather than a linear hand-off, organizations can significantly improve efficiency, reduce risk, and ultimately accelerate the delivery of high-quality, reviewer-friendly submissions.
Intermediate: Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.
Contact the RAPS Support Center:
Call +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email [email protected].

Sr. Director, Transparency and Disclosure, Sr. Director, Transparency and Disclosure


Sr. Director, Transparency and Disclosure, Sr. Director, Transparency and Disclosure
Evan Richardson began his career in the pharmaceutical industry 18 years ago, and today he is the senior director of transparency and disclosure services at Certara. His experience includes drugs, biologics, and medical devices and he has worked for both service providers and in industry across organizations of all sizes. Evan has worn many hats throughout his career, including roles in regulatory affairs, regulatory operations, quality management, and project management. In his current role, Evan leads a global team of subject matter experts supporting Certara’s clients in meeting their regulatory requirements for the disclosure of clinical data.

Sr. Director, Global Submissions, Certara
Mark Bowlby, PhD, has over 25 years of experience in the clinical research and drug development industry. During the last 10 years, he has led many New Drug Applications, Biologics License Applications, and Investigational New Drug (IND) submissions to the Food and Drug Administration and European Medicines Agency. Mark has led the authoring of Investigator’s Brochures (IBs), clinical study reports (CSRs), clinical summaries and overviews, briefing packages, and other regulatory documents. Earlier in his career, Mark planned and wrote numerous biomedical manuscripts, posters, and slides regarding his scientific research and postdoctoral work at Harvard Medical School. His therapeutic areas of expertise include ophthalmology, neurology, psychiatry, and chronic pain. Mark has an expert understanding of drug discovery and development approaches used in the current biopharmaceutical environment.